Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents
View Patent ↗Therapeutically effective anti-viral compositions, useful especially against respiratory diseases caused or mediated by respiratory syncytial virus (RSV) are disclosed, wherein said compositions comprise at least one anti-RSV antibody, including high affinity antibodies, and an additional anti-inflammatory agent, especially corticosteroids, as well as anti-inflammatory antibodies, especially anti-interleukin-6. Also disclosed are methods of using such compositions to treat and/or prevent respiratory diseases. Such compositions may optionally contain other non-antibody anti-viral agents.
1. A method of treating respiratory syncytial virus infection (RSV) in a patient afflicted therewith comprising administering to said patient a therapeutically effective regimen of an anti-RSV antibody and a steroid wherein said regimen is administered systemically.
2. The method of claim 1 wherein the steroid is a corticosteroid.
3. The method of claim 2 wherein said corticosteroid is selected from the group consisting of cortisone, hydrocortisone, prednisone, prednisolone, methylprednisolone, triamcinolone, betamethasone, beclamethasone and dexamethasone.
4. The method of claim 1 wherein the anti-viral antibody is administered in a dosage of 5 to 20 mg/kg body weight.
5. The method of claim 1 wherein the anti-viral antibody is MEDI-493 (palivizumab).
6. The method of claim 1 wherein said steroid is administered in the dosage range is 0.5 mg to 50 mg per kg body weight.
7. The method of claim 1 wherein said steroid is administered in a dosage of 10 μg to 1 gram per kg body weight.
8. The method of claim 1 wherein said antibody and said steroid are administered contemporaneously.
9. The method of claim 1 wherein the antibody is administered prior to administering the steroid.
10. The method of claim 1 wherein the steroid is administered prior to administering the antibody.